Relypsa's patiromer meets in second part of hyperkalemia trial

Relypsa Inc. (Redwood City, Calif.) said twice-daily oral patiromer ( RLY5016) plus renin-angiotensin-aldosterone system (RAAS) inhibitor therapy met the primary endpoint in the second part of a two-part Phase III trial to treat hyperkalemia in chronic kidney disease (CKD) patients. Patiromer reduced serum potassium levels from baseline at week 4, the start of the second part of the trial, to week 8 vs. placebo (p<0.001). Last month, Relypsa said patiromer plus RAAS inhibitor therapy met the primary endpoint in the first part of the trial of reducing serum potassium levels at week four compared to baseline. ...